Publication of Annual Report 2023 & Notice of AGM

November 17, 2023
RNS Number : 8806T
Renalytix PLC
17 November 2023


Renalytix plc

("Renalytix" or the "Company")


Publication of Annual Report 2023 and Notice of 2023 Annual General Meeting


LONDON and SALT LAKE CITY, UT November, 17 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Annual Report for the year ended 30 June 2023 and the Notice of 2023 Annual General Meeting ("AGM") have now been published on the Company's website: and, and posted to shareholders who have not consented to receive electronic communications.


The AGM will be held in-person on 15 December 2023 at 15.30 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD. 


To help with practical arrangements for the AGM, any shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at or by telephone at +44 (0)20 7933 8790.


For further information, please contact:


Renalytix plc

James McCullough, CEO

Via Walbrook PR


Stifel (Nominated Adviser, Joint Broker)

Tel: 020 7710 7600

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea



Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

Walbrook PR Limited

Tel: 020 7933 8780 or

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07407 804 654

CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or


About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit





This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.